BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Mesoblast Limited Provides Corporate Strategy for Product Development to Treat Neurologic Conditions


6/8/2012 10:29:28 AM

Melbourne, Australia; 8 June 2012: Mesoblast Limited (ASX:MSB) today outlined the Company’s strategic plans to develop adult stem cell therapies for neurodegenerative diseases at the Jefferies Global Healthcare Conference in New York.

In an update on Mesoblast’s strategic alliance with Teva Pharmaceutical Industries Ltd in the fields of neurologic and cardiovascular diseases, Chief Executive Professor Silviu Itescu discussed plans to commercially develop Mesoblast’s proprietary allogeneic, or off-the-shelf, adult dental pulp stem cells (DPSC) for stroke, spinal cord injury, Parkinson’s and Huntington’s diseases.

Mesoblast has exclusive worldwide commercial rights to granted composition of matter patents covering DPSC, which are STRO-1 positive Mesenchymal Precursor Cells (MPCs) of neural crest origin. These cells produce significantly greater levels of neurotrophic factors and are significantly more effective than other adult stem cell types for neural differentiation and repair of various neural cells and tissues.

Recent published reports have shown that DPSC may be effective for protection and repair of neural tissue after spinal cord injury and stroke.

Professor Itescu additionally updated attendees on outcomes from recent meetings with regulatory authorities in the United States and Europe in regards to the upcoming commencement of the congestive heart failure Phase 3 trial. He said that the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA) were aligned on the clinical trial design and the primary and secondary endpoints.

A copy of the presentation to the conference is attached.

About Mesoblast

Mesoblast Limited (ASX:MSB) is a world leader in commercialising biologic products for the broad field of regenerative medicine. Mesoblast has the worldwide exclusive rights for a series of patents and technologies developed over more than 10 years relating to the identification, extraction, culture and uses of adult Mesenchymal Precursor Cells (MPCs).

www.mesoblast.com

For further information, please contact:

Julie Meldrum

Corporate Communications

Mesoblast Limited

T: + 61 (0) 3 9639 6036

E: julie.meldrum@mesoblast.com

For media queries, please contact:

Melanie Toyne Sewell/Gemma Howe

College Hill

T: + 44 20 7866 7860

E: mesoblast@collegehill.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES